VKORC1 Genotype

If you are starting warfarin, already taking it, or might need it after a future heart valve replacement, blood clot, or atrial fibrillation diagnosis, your VKORC1 (vitamin K epoxide reductase complex subunit 1) genotype helps explain why the same starting dose can leave one person under-anticoagulated and send another to the emergency room with bleeding. Two people of the same age, weight, and diet can need warfarin doses that differ by more than two-fold, and a single inherited variant in this gene accounts for a large share of that gap.

VKORC1 alone explains roughly a quarter to a third of the differences in warfarin dose between people, and combined with other genetic and clinical factors, the share approaches half. Knowing your genotype before you need warfarin turns a trial-and-error process into a planned one.

What VKORC1 Actually Does

VKORC1 encodes an enzyme that recycles vitamin K inside your liver cells. Vitamin K is the cofactor your body uses to switch on the clotting proteins that stop bleeding. Warfarin works by blocking this exact enzyme, which is why genetic variation in the gene matters so much for how the drug behaves in your body.

The most studied variants sit just outside the protein-coding region of the gene. The promoter variant called -1639G>A (sometimes labeled rs9923231) and an intronic variant called 1173C>T travel together almost perfectly, and either one can be used as a marker for the same underlying difference: how much VKORC1 enzyme your liver makes. People who inherit the A version make less of the enzyme, which means warfarin needs less work to shut it down.

Warfarin Dose and Bleeding Risk

The dose differences linked to VKORC1 genotype are large enough to matter clinically from day one. In one landmark study, average warfarin doses were 6.7 mg per day for people with the GG genotype, 4.3 mg for GA, and 2.7 mg for AA. A separate analysis using the 1173C>T marker found the same pattern: 6.2 mg for CC, 4.8 mg for CT, and 3.5 mg for TT. Using the haplotype grouping system, doses fell from 6.2 mg per day for the high-dose B/B group to 2.7 mg per day for the low-dose A/A group.

That dose spread translates to real bleeding risk if your doctor starts you on a standard dose without knowing your genotype. People homozygous for the low-dose A haplotype had about four and a half times the odds of an INR (international normalized ratio, the standard blood test for warfarin) above 5, a threshold that signals dangerous over-anticoagulation. They also reached their first therapeutic INR faster and crossed the over-anticoagulation line faster, often within the first weeks of starting the drug.

Sources: Zhu et al. (Clinical Chemistry, 2007); Rieder et al. (NEJM, 2005).

What this means for you: if you carry one or two A alleles, your prescriber should consider starting you on a lower warfarin dose and checking your INR more frequently in the first week. Genotype-guided dosing in randomized trials produced more time in the therapeutic INR range during initiation than standard dosing did.

Acenocoumarol and Phenprocoumon

VKORC1 genotype also influences sensitivity to other vitamin K antagonists used outside the US. Genotype-guided algorithms for phenprocoumon and acenocoumarol explained 55.9% and 52.6% of dose variation, respectively, compared with about 17.3% and 23.7% using only clinical factors like age, weight, and interacting drugs. The clinical trial evidence is more mixed for these drugs than for warfarin: a randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon (Verhoef et al., NEJM 2013) found no significant improvement in 12-week time in the therapeutic range (61.6% vs. 60.2%), although a benefit appeared in the first four weeks. If you live in Europe or have used these drugs abroad, the same genotype information applies, with this caveat in mind.

Ethnic Differences in the Variant

VKORC1 variant frequencies differ dramatically by ancestry, which is one reason warfarin dose averages differ by population. The low-dose VKORC1*2 allele appears in about 42% of Europeans, 95% of Chinese, and 14% of African Americans. In a separate comparison, the AA genotype at -1639 was found in about 80% of Chinese participants versus 14% of Caucasians.

This is why average dose recommendations from European trials should not be applied uncritically to Asian or African-ancestry patients. It also means that in some Black African populations, additional variants outside VKORC1 and CYP2C9 contribute to dose variation, so a genotype panel built around European data may miss part of the picture.

Rare Resistance Mutations

A separate category of much rarer VKORC1 mutations causes the opposite problem: warfarin resistance. These are coding changes in the gene rather than the common promoter or intronic variants. Researchers have catalogued at least 13 novel mutations associated with the resistance phenotype, including variants like D36Y and L128R, where patients need very high doses to reach a therapeutic INR. D36Y, while uncommon in most populations, has a minor allele frequency of about 5% in Ashkenazi Jewish populations. Standard pharmacogenomic panels are designed mainly to detect the common low-dose variants and may not flag these rare resistance mutations.

Beyond Anticoagulation: Other Associations

The most established use of VKORC1 testing is for warfarin dosing, but research has explored other associations. The rs9923231 variant has been linked to higher osteoporosis risk in postmenopausal women in observational research, with the homozygous and allelic models showing increased risk, though other studies have not found an association. A separate observational study in sarcoidosis patients found that the C1173T variant was associated with higher risk of kidney stones. These findings are early and not the primary reason to order this test, but they hint that vitamin K recycling matters beyond clotting.

One-Time Result, Lifetime Use

VKORC1 genotype is fixed at conception and does not change over your lifetime. You order this test once, and the result applies to every future encounter with warfarin or related drugs. There is no value in retesting the genotype itself, though if you receive a result from a direct-to-consumer service like 23andMe and want to use it for medical dosing decisions, a confirmatory test from a clinical-grade lab is reasonable.

Where ongoing tracking matters is for the downstream phenotype if you actually start warfarin: the INR. INR should be monitored frequently when therapy starts (often every few days for the first weeks) and at least monthly once your dose is stable. Your VKORC1 result helps your prescriber choose a starting dose and predict how quickly you will respond, but it does not replace INR monitoring.

Decision Pathway for an Unexpected Result

If your VKORC1 result identifies you as a low-dose responder (one or two A alleles at -1639, or one or two T alleles at 1173), the actionable next steps are: pair the result with CYP2C9 genotyping if you have not already, since the two genes together explain more variation than either alone; share the result with any prescriber who may consider warfarin for atrial fibrillation, deep vein thrombosis, pulmonary embolism, or mechanical heart valves; and ask whether a direct oral anticoagulant might be appropriate instead, since these drugs do not require VKORC1-informed dosing.

If your result identifies a rare resistance mutation or a variant of uncertain significance, a hematologist or pharmacogenomics-trained pharmacist can help interpret what the change means for your specific case. Standard warfarin dosing algorithms may not apply. Biological relatives, particularly siblings and children, may benefit from knowing this finding before they encounter warfarin themselves.

What Standard Panels Miss

Most clinical pharmacogenomic panels test for the common -1639G>A or 1173C>T variants. They do not sequence the entire VKORC1 gene. A negative result on a standard panel tells you that you do not carry the common low-dose variant; it does not rule out a rare coding mutation that could affect your warfarin response. For most people, this distinction does not matter, because rare resistance mutations are uncommon. For someone with a family history of unusual warfarin requirements, deeper sequencing may be warranted.

When Results Can Be Misleading

VKORC1 testing is largely free from the day-to-day confounders that affect dynamic biomarkers, but a few things can still produce a misleading interpretation. The most important ones to know:

• Variant panel coverage: the assay only detects the specific variants it is designed to detect. A standard pharmacogenomic test that reports a single SNP at -1639 will not catch rare resistance mutations elsewhere in the gene.
• Ancestry-specific allele frequencies: the clinical meaning of an AA result depends on the dose distribution in your ancestral population. A genotype calculator built on European data may give imprecise estimates for someone of Asian or African ancestry.
• Direct-to-consumer versus clinical-grade testing: a 23andMe-style report that mentions VKORC1 is informational, not a clinical result. If you intend to use the result for warfarin dosing, request a clinical-grade test or confirmatory sequencing.
• Variants of uncertain significance: if a panel reports an unexpected change in VKORC1 with unknown clinical meaning, that result needs interpretation by a specialist, not a standard dosing algorithm.